|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
四十己过 发表于 2017-5-1 05:20 
真？假？
真？闻玉梅教授是乙肝治疗性疫苗的先驱,国际知名和尊重.
假？YIC是成功.
"An antigen–antibody (HBsAg–HBIG) complex therapeutic vaccine candidate with alum as
adjuvant first showed promising results in a double-blind, placebo-controlled, phase IIb clinical trial, but results of a phase III clinical trial including 450 patients were disappointing [33]. This is most likely due to the fact that subviral particle vaccines with alum-based adjuvants
preferentially induce antibody but not cytotoxic T cell responses that would be required for therapeutic efficacy"
抗原抗体（HBsAg-HBIG）具有明矾的复杂治疗性候选药物佐剂首先在双盲中显示出有希望的结果，安慰剂对照，IIb期临床试验，但包括450例患者在内的III期临床试验结果令人失望[33]。 这很可能是由于这个事实具有明矾助剂的亚病毒颗粒疫苗优先诱导抗体而不是细胞毒性T细胞治疗效果所需的反应.
从过去的失败中学习, 新的治疗性疫苗继续被研究，许多新的临床试验.
Optimized therapeutic vaccination strategies for hepatitis B.
A potent therapeutic vaccination to treat chronic HBV infection will require several steps: (i) pretreatment with antivirals to control HBV viremia and
liver inflammation, or HBV-specific siRNAs to suppress viremia and antigenemia; this shall facilitate the induction of immune responses by
vaccination and limit vaccine-induced inflammatory responses; (ii) protein priming with recombinant HBV antigens to induce HBV-specific antibodies and prime T-cell responses; this shall reduce the antigen load and prevent de novo infection of hepatocytes; (iii) boosting with a recombinant viral vector vaccine (e.g. MVA) encoding HBV antigens; this shall induce a broad and robust CD8 T-cell response to eliminate HBVinfected hepatocytes and achieve long-term immune control; (iv) optional: additional strategies to overcome T cell exhaustion (e.g. checkpoint inhibition or iMATE induction.
优化乙型肝炎疫苗接种策略治疗慢性HBV感染的强效治疗性疫苗将需要几个步骤：（i）用抗病毒剂预处理以控制HBV病毒血症，肝脏炎症或HBV特异性siRNA来抑制病毒血症和抗原血症; 这将有利于诱导免疫反应疫苗接种和限制疫苗诱导的炎症反应; （ii）用重组HBV抗原诱导HBV特异性的蛋白质引发抗体和主要T细胞应答; 这将降低抗原负荷并防止肝细胞的新生感染; （iii）用a编码HBV抗原的重组病毒载体疫苗（例如MVA）; 这将诱导广泛而强大的CD8 T细胞应答来消除HBV感染肝细胞，实现长期免疫控制; （iv）可选：克服T细胞衰竭的其他策略（例如检查点抑制或iMATE诱导。
引用自:
Current Opinion in Virology
Volume 24, June 2017, Pages 38–45
Novel viral and host targets to cure hepatitis B
Chunkyu Ko1, Thomas Michler1, 2, Ulrike Protzer1, 2,
https://doi.org/10.1016/j.coviro.2017.03.019
当代病毒学观点
第24卷，2017年6月，第38-45页
新型病毒和宿主对象来治愈乙型肝炎
Chunkyu Ko1，Thomas Michler1,2，Ulrike Protzer1,2，
https://doi.org/10.1016/j.coviro.2017.03.019 |
|
楼主: MP4
发表于 2017-5-2 01:34
